Advertisement

Topics

Agilis Biotherapeutics, Inc. Company Profile

23:49 EDT 18th June 2019 | BioPortfolio

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis’ gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targeting and restoration of lost gene function to achieve long-term efficacy. Agilis’ rare disease programs are focused on gene therapy for AADC deficiency, Friedreich’s ataxia, and Angelman syndrome, all rare genetic diseases that include neurological deficits and result in physically debilitating conditions.


News Articles [233 Associated News Articles listed on BioPortfolio]

Agilis Biotherapeutics enters license agreement with the University of South Florida

Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD,...

Evotec to acquire biologics company Just Biotherapeutics

Evotec has entered a definitive agreement to acquire Just Biotherapeutics and its in-house drug development technology platform J.DESIGN. Just Biotherapeutics provides machine-learning...Read More.....

Evotec Pays $90 Million for Just Biotherapeutics

German drug discovery and development company Evotec has signed an agreement to buy Just Biotherapeutics, a US biologics company. Founded in 2014, Just Biotherapeutics is backed by investors that incl...

DGAP-Adhoc: Evotec SE akquiriert Just Biotherapeutics, Inc. (deutsch)

Evotec SE akquiriert Just Biotherapeutics, Inc. DGAP-Ad-hoc: Evotec SE / Schlagwort(e): Firmenübernahme Evotec SE akquiriert Just Biotherapeutics, Inc. 20.05.2019 / 22:24 CET/CEST Veröffentlichung ....

Iovance Biotherapeutics to build cell therapies plant in US

Iovance Biotherapeutics has announced plans to construct a commercial-scale production facility in Philadelphia, US. This 136,000ft2 plant will be used...Read More... The post Iovance Biotherapeutics ...

FDA fast-tracks Iovance Biotherapeutics' cervical cancer drug

Iovance Biotherapeutics' LN-145, which is in midstage development to treat patients with recurrent or metastatic cervical can -More- 

Evotec kauft Just Biotherapeutics für bis zu 81 Mio EUR

FRANKFURT (Dow Jones)--Evotec kauft in den USA zu. Für umgerechnet bis zu 81 Millionen Euro übernimmt das Unternehmen die in Seattle ansässige Just Biotherapeutics. Der Kaufpreis schließe eine pot...

Evotec To Buy Just Biotherapeutics For Up To US$90 Mln

HAMBURG (dpa-AFX) - Evotec SE (EVTCY.PK, EVOTF.PK) said that it agreed to acquire Just Biotherapeutics Inc. based in Seattle, WA, USA for up to US$90 million or about 81 million euros including po...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Atryn [gtc biotherapeutics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Winrho [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use WinRho SDF safely and effectively. See full prescribing information for WinRho SDF. WinRho SDF [Rho(D) Immune Globulin Intravenous (Hu...

Ixinity [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use IXINITY® safely and effectively. See full prescribing information for IXINITY.. IXINITY [coagulation factor IX (recombinant)] Lyophil...

PubMed Articles [20 Associated PubMed Articles listed on BioPortfolio]

Acceleration of rare disease therapeutic development: a case study of AGIL-AADC.

Rare-disease drug development is both scientifically and commercially challenging. This case study highlights Agilis Biotherapeutics (Agilis), a small private biotechnology company that has developed ...

Chemical Characterization and Biotechnological Applicability of Pigments Isolated from Antarctic Bacteria.

Considering the global trend in the search for alternative natural compounds with antioxidant and sun protection factor (SPF) boosting properties, bacterial carotenoids represent an opportunity for ex...

Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region.

The development of biotherapeutics requires continuous improvement in analytical methodologies for the assessment of their quality attributes. A subset of biotherapeutics is designed to interact with ...

Reliable LC-MS Multi-Attribute Method for Biotherapeutics by Run-Time Response Calibration.

A major challenge of a mass spectrometry-based quantitative multi-attribute method (MAM) for biotherapeutics is its high variability between instruments. For reproducible attribute measurements, not o...

Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies.

Clinical development of biotherapeutics for combination therapy requires monitoring the concentrations of both drugs in biological samples. Traditionally, two assays are required to measure drug level...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety Study on Agilis NxT Introducer in AF Patients

To prove if the success rate of curative treatment of atrial fibrillation in left atrial circumferential pulmonary vein ablation is higher by using a steerable transseptal introducer givin...

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [108 Associated Companies listed on BioPortfolio]

Agilis Biotherapeutics, LLC

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affect...

Agilis Biotherapeutics, Inc.

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central ner...

Agilis Biotherapeutics and GTRI

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central ner...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

EpimAb Biotherapeutics EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunogl...

More Information about "Agilis Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Agilis Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Agilis Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Agilis Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Agilis Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Agilis Biotherapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record